Have you jumped on any of these gainers, or missed the boat? Which sector do you think will spawn the next batch of double-digit gainers: biotech breakthroughs or AI infrastructure? Share your picks below! The 2026 US stock market kicked off with intense volatility, but as of the end of February, the S&P 500 has recovered all losses, closing just 1.8% below its all-time high. Looking back at 2025, the index rose more than 16% for the year, delivering returns above its long-term average for the third consecutive year. Entering the new year, investors are eagerly anticipating this upward momentum to continue. Amid sector rotation, companies with unique catalysts have stood out as market focal points. Year-to-date, biotech firms with major clinical progress in the healthcare sector, along

$Alumis Inc.(ALMS)$  $Bristol-Myers Squibb(BMY)$  $Arcutis Biotherapeutics Inc.(ARQT)$  🚀🧬📊 $ALMS Repriced, Not Rallied: Phase 3 Dominance Ignites Volatility Expansion and Price Discovery 📊🧬🚀 I’m treating today’s move in Alumis Inc ($ALMS) as a live, in-session repricing event, not a completed story. With the market still open, price, volume, and flow continue to confirm a regime shift rather than a one-day headline reaction. $ALMS is up +106.5% to ~$17.16 after its lead oral TYK2 inhibitor delivered a decisive Phase 3 outcome in the ONWARD1 and ONWARD2 plaque psoriasis trials. Around 65% PASI 90 and more than 40%